Prostate cancer is a major health care problem worldwide, especially in the industrialized
countries of the Western world. The estimates for the year 2000 (Table 1) indicate a …

" We have seen mortality rising for a number of years, especially among African-American
men who have more than double the mortality rate of white men," Edwards said." So we …

OBJECTIVES: Randomized controlled trials are currently conducted to assess whether the
mortality from prostate cancer is reduced by early detection with the use of prostate-specific …

Screening for prostate cancer with prostate-specific antigen (PSA), a simple blood test, is
complex, controversial, intellectually challenging and ethically concerning. Sweden has …

Study objectives The European Randomized Study of Screening for Prostate Cancer
(ERSPC) was initiated in 1994 with the aim of using serum PSA levels to screen for prostate …

PURPOSE: In the last 2 decades there has been increasing awareness of and research on
prostate cancer. We considered prostate cancer in the context of other major causes of …

OBJECTIVES: The efficacy of screening for prostate cancer (PCa) with digital rectal
examination (DRE) and prostate-specific antigen (PSA) measurement has not been proved …

In the United States, most men over the age of 50 years have had a prostate-specific antigen
(PSA) test, 1 despite the absence of evidence from large, randomized trials of a net benefit …

Prostate cancer is the most prevalent malignancy in men and the third leading cause of
cancer deaths worldwide. Although the wide-spread introduction of total prostate-specific …

Prostate specific antigen has profoundly affected the detection of prostate cancer in the
United States. First identified in 1970, it was initially used to measure the response to …